Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma

This multicenter pilot study assessed the safety and efficacy of brentuximab vedotin (BV) and AVD (adriamycin, vinblastine, and dacarbazine) followed by 30 Gy involved site radiation therapy (ISRT). Patients with newly diagnosed, early stage classical Hodgkin lymphoma (HL) with unfavorable-risk feat...

全面介紹

Na minha lista:
書目詳細資料
發表在:Blood
Main Authors: Kumar, Anita, Casulo, Carla, Yahalom, Joachim, Schöder, Heiko, Barr, Paul M., Caron, Philip, Chiu, April, Constine, Louis S., Drullinsky, Pamela, Friedberg, Jonathan W., Gerecitano, John F., Hamilton, Audrey, Hamlin, Paul A., Horwitz, Steven M., Jacob, Alexandra G., Matasar, Matthew J., McArthur, Gianna N., McCall, Susan J., Moskowitz, Alison J., Noy, Ariela, Palomba, Maria L., Portlock, Carol S., Straus, David J., VanderEls, Nicholas, Verwys, Stephanie L., Yang, Joanna, Younes, Anas, Zelenetz, Andrew D., Zhang, Zhigang, Moskowitz, Craig H.
格式: Artigo
語言:Inglês
出版: American Society of Hematology 2016
主題:
Clinical Trials and Observations
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5025897/
https://ncbi.nlm.nih.gov/pubmed/27458003
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-03-703470
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍